Palvella Therapeutics, Inc. (PVLA)

NASDAQ: PVLA · Real-Time Price · USD

44.64

+1.43 (3.31%)

At close: Aug 13, 2025, 4:00 PM

45.53

+0.89 (1.99%)

Pre-market: Aug 14, 2025, 9:02 AM EDT

Palvella Therapeutics Employees

Palvella Therapeutics had 14 employees as of December 31, 2024.

Employees

14

Change

n/a

Growth

n/a

Revenue / Employee

n/a

Profits / Employee

-$1,634,929

Market Cap

493.52M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	14	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

PVLA News

1 hour ago - Palvella Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
7 days ago - Palvella Therapeutics to Host Second Quarter 2025 Financial Results and Corporate Update Conference Call on August 14, 2025 - GlobeNewsWire
9 days ago - Palvella Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference - GlobeNewsWire
6 weeks ago - Palvella Therapeutics Added to Russell 3000® and Russell 2000® Indexes - GlobeNewsWire
7 weeks ago - Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25% - GlobeNewsWire
2 months ago - Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors - GlobeNewsWire
2 months ago - Palvella Therapeutics Receives Initial Proceeds from FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations - GlobeNewsWire
2 months ago - Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer - GlobeNewsWire